Febrile Neutropenia Global Market Report 2025

The febrile neutropenia market size has grown strongly in recent years. It will grow from $10.6 billion in 2024 to $11.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to factors such as the rising incidence of cancer, the growing adoption of chemotherapy, the expansion of personalized medicine, efforts to reduce healthcare costs, and the increasing prevalence of neutropenia.

The febrile neutropenia market size is expected to see strong growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the growing use of immunosuppressive drugs, increasing research and development (R&D), favorable reimbursement policies, rising investments, and the increasing incidence of leukemia cases. Key trends during this period include rapid molecular diagnostics, the adoption of antimicrobial stewardship and de-escalation therapy, immunotherapy and targeted treatments, the development of risk stratification models, and advancements in fungal biomarkers.

The growing prevalence of cancer is expected to drive the growth of the febrile neutropenia market in the coming years. Cancer is a complex set of diseases marked by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread throughout the body. The rising incidence of cancer is largely due to factors such as an aging population, environmental and occupational exposures, genetic predisposition, and hormonal and reproductive factors. Febrile neutropenia plays a critical role in supporting cancer patients by highlighting the increased risk of infections during chemotherapy, encouraging early intervention, and enabling targeted treatments to prevent life-threatening complications. This helps improve patient outcomes and ensures timely continuation of cancer therapies. For example, in January 2022, the American Cancer Society reported that in the U.S., an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths were expected, with nearly 1,670 deaths occurring daily. Therefore, the increasing prevalence of cancer is driving the growth of the febrile neutropenia market.

Key players in the febrile neutropenia market are focusing on the development of advanced biosimilar drugs to increase treatment accessibility. Biosimilar drugs are biologics that closely mirror approved reference drugs in structure, function, and efficacy. They provide cost-effective alternatives to original biologics, improving patient access while complying with stringent regulatory standards. For instance, in September 2022, Fresenius Kabi, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for its biosimilar Stimufend (pegfilgrastim-fpgk). This approval allows Stimufend to be used in patients with non-myeloid malignancies who are undergoing myelosuppressive chemotherapy, which can lead to febrile neutropenia, a condition characterized by a low white blood cell count and fever. The company plans to launch Stimufend in a prefilled syringe format in early 2023 and is also developing an on-body injector for future use.

In July 2023, Assertio Holdings Inc., a U.S.-based pharmaceutical company, acquired Spectrum Pharmaceuticals for an undisclosed amount. This acquisition is aimed at expanding and diversifying Assertio's revenue base, enhancing its oncology portfolio with ROLVEDON (eflapegrastim-xnst) injection, and strengthening its commercial and digital marketing capabilities. Spectrum Pharmaceuticals is a U.S.-based company specializing in the manufacture of febrile neutropenia drugs.

Major players in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech.

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the febrile neutropenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Febrile neutropenia is a medical condition characterized by a fever (a temperature of 100.4°F or higher) and a low count of neutrophils, which are essential white blood cells needed to fight infections. This condition is commonly seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more susceptible to infections.

The main treatment approaches for febrile neutropenia include empirical antibiotic therapy, targeted antibiotic therapy, and supportive care. Empirical antibiotic therapy involves initiating treatment with broad-spectrum antibiotics based on clinical assessment before identifying the exact causative pathogen. The condition is associated with various risk factors, such as chemotherapy-induced neutropenia, transplant-related neutropenia, and genetic disorders, with several potential etiologies including gram-negative bacteria, gram-positive bacteria, fungal infections, and viral infections. Diagnosis is made using various methods, such as blood cultures, imaging tests, and bone marrow aspiration.

The febrile neutropenia market research report is one of a series of new reports that provides febrile neutropenia market statistics, including the febrile neutropenia industry global market size, regional shares, competitors with the febrile neutropenia market share, detailed febrile neutropenia market segments, market trends, and opportunities, and any further data you may need to thrive in the febrile neutropenia industry. This febrile neutropenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The febrile neutropenia market consists of revenues earned by entities by providing services such as diagnostic services, hematologic support, hospitalization and monitoring, and outpatient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The febrile neutropenia market also includes sales of antibiotics, antifungal and antiviral medications, urinalysis, and urine culture. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.